A real-time urine tenofovir assay improves drug adherence among people with HIV with prior virologic failure in a randomized controlled trial.

Introduction: Scalable strategies to detect and address inadequate adherence to antiretroviral therapy (ART) are a high priority towards meeting UNAIDS 95-95-95 targets. A urine tenofovir rapid assay (UTRA) at the point-of-care improves adherence among PrEP recipients and virologic suppression (VS) in a pre-post study of people with HIV (PWH). Here, we conducted the first randomized trial of UTRA- enhanced adherence support vs standard of care among PWH.